This study is the first retrospective, long-term analysis of metformin as adjuvant therapy to insulin in patients with T1DM.

What should you add to prevent a loss of limb?

This sweet treat may be future aid in diabetes treatment.

Medication showed significant reduction in risk for cardiovascular death, hospitalization for worsening heart failure.

Study finds connection between duration of therapy in senior patients and development of neurodegenerative disease.

When it comes to antidiabetic therapies, professionals should be aware of safety concerns with concentrated insulin formulations, metformin and renal function, and SGLT-2 inhibitors and DKA. See the breakdown of these safety issues by Tom Palma, RPh, MS, BCPS, and Greg Wiggers, PharmD, PhD, plus exclusive commentary by DIC Advisory Board member Dr. George Bakris.

When diagnosing suspected nonalcoholic fatty liver disease (NAFLD), hepatic steatosis and inflammation with hepatocellular injury is an indication of which one of the following? A. Nonalcoholic fatty liver (NAFL) B. Nonalcoholic steatohepatitis (NASH) C. Both of the above D. None of the above Follow the link to see the correct answer!

When was the last time you rode a bike? Follow the link to see how you compare to your colleagues!

We all know of patients who walk around with glucose levels of 400mg/dl without any problems functioning. Most of our patients are often 100-200 points too high and they don’t even know it. When we start them on insulin, we usually go slow for fear of hypoglycemia, as often it …

Female, 26 years of age, type 1 diabetes for 15 years, well-educated, uses insulin pump. Recent A1C 7.6%; has been rising from 6 to 6.5. Thinks her mealtime insulin is not working fast enough. She does bolus about 20 minutes before eating. Assessed pump, CGM, food intake and activity. Her report seemed to be the case.